Significant Itch Relief

A total of 251 adolescents in Trial 6 (16 weeks) with moderate-to-severe atopic dermatitis inadequately controlled with topical prescription therapies were randomized to DUPIXENT or placebo. Adolescents ≥60 kg received DUPIXENT 300 mg Q2W after a 600 mg loading dose, and adolescents <60 kg received 200 mg Q2W after a 400 mg loading dose. An endpoint included the reduction in itch as defined by ≥4-point improvement in the Peak Pruritus NRS at Week 16.1,2

Significant Itch Relief for Uncontrolled Moderate-to-Severe Atopic Dermatitis

12-17 years

Significant itch reduction (Peak Pruritus NRS) at Week 16 with DUPIXENT in Trial 6 (secondary endpoint)1-3,a,b

The safety and efficacy of DUPIXENT were generally consistent between adolescents and adults1

  1. Full Analysis Set includes all subjects randomized.
  2. In the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders (59% and 21% in the placebo and DUPIXENT arms, respectively).

Pruritus NRS assesses the average itch intensity over the previous 24 hours4

A patient-reported measure that uses a 0- to 10-point scale, with which patients are asked4:


“On a scale of 0 to 10, how would you rate your itch overall (on average) during the previous 24 hours?”

None
The Worst
Imaginable

A reduction of at least 4 points in pruritus NRS from baseline is a clinically meaningful change.1

EASI, Eczema Area and Severity Index; NRS, numerical rating scale.

Dosing and
Administration
Thinking about prescribing
DUPIXENT? Find the information you
need to get started.
Start Now
Connect With a Rep Have questions about DUPIXENT? Get
answers from a representative.
Request a Visit
DUPIXENT MyWay Get patient access support
and information about benefits
investigations, prior authorizations,
and Medical Necessity and
appeal letters.
Explore Patient Support Resources
References:
  1. DUPIXENT Prescribing Information.
  2. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44-56.
  3. Data on file, Regeneron Pharmaceuticals, Inc.
  4. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502-507.